Axsome Therapeutics (AXSM) said Monday that it expects total product revenue of about $196 million for Q4, up 65% from a year earlier.
Analysts surveyed by FactSet expect Q4 revenue of $187.3 million.
Auvelity, a treatment for major depressive disorder, is expected to generate about $155.1 million in Q4 net product sales, the company said.
Analysts surveyed by FactSet are expecting $149 million in Q4 Auvelity sales.
Axsome shares were 0.9% higher in premarket trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments